These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23385843)

  • 21. Cardiovascular health and economic effects of smoke-free workplaces.
    Ong MK; Glantz SA
    Am J Med; 2004 Jul; 117(1):32-8. PubMed ID: 15210386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tobacco control since the 1964 Surgeon General's Report: reflecting back and looking forward.
    Mulshine JL; Healton C
    Oncology (Williston Park); 2014 Mar; 28(3):180, 182-3, 210. PubMed ID: 24855724
    [No Abstract]   [Full Text] [Related]  

  • 23. The partial smoking ban in licensed establishments and health inequalities in England: modelling study.
    Woodall AA; Sandbach EJ; Woodward CM; Aveyard P; Merrington G
    BMJ; 2005 Sep; 331(7515):488-9. PubMed ID: 16113033
    [No Abstract]   [Full Text] [Related]  

  • 24. If you try to stop smoking, should we pay for it? The cost-utility of reimbursing smoking cessation support in the Netherlands.
    Vemer P; Rutten-van Mölken MP; Kaper J; Hoogenveen RT; van Schayck CP; Feenstra TL
    Addiction; 2010 Jun; 105(6):1088-97. PubMed ID: 20659063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Providers issue brief: tobacco: public place smoking: year end report-2003.
    McKinley A
    Issue Brief Health Policy Track Serv; 2003 Dec; ():1-12. PubMed ID: 14969271
    [No Abstract]   [Full Text] [Related]  

  • 26. Smoking bans and the secondhand smoking problem: an economic analysis.
    Hofmann A; Nell M
    Eur J Health Econ; 2012 Jun; 13(3):227-36. PubMed ID: 21842184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic evaluation and the postponement of health care costs.
    van Baal PH; Feenstra TL; Polder JJ; Hoogenveen RT; Brouwer WB
    Health Econ; 2011 Apr; 20(4):432-45. PubMed ID: 21210494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.
    Athanasakis K; Igoumenidis M; Karampli E; Vitsou E; Sykara G; Kyriopoulos J
    Clin Ther; 2012 Aug; 34(8):1803-14. PubMed ID: 22818870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Political work to reduce the use of tobacco is not easy. "If tobacco was a medication it would no longer be available on the market"].
    Westerholm B
    Lakartidningen; 2002 Jul; 99(30-31):3103-4. PubMed ID: 12198927
    [No Abstract]   [Full Text] [Related]  

  • 30. The impact of public smoking ban on the incidence of myocardial infarction hospitalizations.
    Khawaja O; Al-Mallah M
    Rev Cardiovasc Med; 2010; 11(3):e121-9. PubMed ID: 21045764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A New York bill for regulation of electronic cigarettes.
    Yaqub F
    Lancet Oncol; 2014 Feb; 15(2):e56. PubMed ID: 24627910
    [No Abstract]   [Full Text] [Related]  

  • 32. Cost-effectiveness analysis of a European primary-care physician training in smoking cessation counseling.
    Pinget C; Martin E; Wasserfallen JB; Humair JP; Cornuz J
    Eur J Cardiovasc Prev Rehabil; 2007 Jun; 14(3):451-5. PubMed ID: 17568248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economics of smoking cessation.
    Parrott S; Godfrey C
    BMJ; 2004 Apr; 328(7445):947-9. PubMed ID: 15087348
    [No Abstract]   [Full Text] [Related]  

  • 34. A new opportunity to eliminate policy incoherence in tobacco control in New Zealand.
    Wilson N; Thomson G; Blakely T; Edwards R
    N Z Med J; 2010 Mar; 123(1311):89-92. PubMed ID: 20360804
    [No Abstract]   [Full Text] [Related]  

  • 35. After the smoke has cleared: evaluation of the impact of a new national smoke-free law in New Zealand.
    Edwards R; Thomson G; Wilson N; Waa A; Bullen C; O'Dea D; Gifford H; Glover M; Laugesen M; Woodward A
    Tob Control; 2008 Feb; 17(1):e2. PubMed ID: 18218788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of tobacco control policies in Vietnam: the case of personal smoking cessation support.
    Higashi H; Barendregt JJ
    Addiction; 2012 Mar; 107(3):658-70. PubMed ID: 21883602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New Zealand's Primary Health Care Strategy: what are the costs and how likely are the benefits?
    Raymont A; Cumming J
    N Z Med J; 2003 May; 116(1173):U416. PubMed ID: 12740610
    [No Abstract]   [Full Text] [Related]  

  • 38. Smoke-free bars in Ireland: a runaway success.
    Howell F
    Tob Control; 2005 Apr; 14(2):73-4. PubMed ID: 15791009
    [No Abstract]   [Full Text] [Related]  

  • 39. Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold.
    Neumann PJ; Cohen JT; Weinstein MC
    N Engl J Med; 2014 Aug; 371(9):796-7. PubMed ID: 25162885
    [No Abstract]   [Full Text] [Related]  

  • 40. A report on the New South Wales Tobacco Action Plan 2001-2004.
    Mitchell JA; Hailstone S
    N S W Public Health Bull; 2004; 15(5-6):95-8. PubMed ID: 15543241
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.